Marshall Wace’s Metagenomi Therapeutics MGX Stock Holding History

Marshall Wace’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$36.9K	Sell	27,521 -51,615	-65%	-$80.2K	﹤0.01%	3005
2025 Q4	$128K	Sell	79,136 -12,169	-13%	-$26.3K	﹤0.01%	2676
2025 Q3	$216K	Sell	91,305 -58,989	-39%	-$120K	﹤0.01%	2549
2025 Q2	$222K	Buy	+150,294	New	+$235K	﹤0.01%	2428
2025 Q1	–	Sell	-47,922	Closed	-$173K	–	3166
2024 Q4	$173K	Sell	47,922 -120,717	-72%	-$291K	﹤0.01%	2378
2024 Q3	$366K	Hold	168,639	–	–	﹤0.01%	2054
2024 Q2	$688K	Sell	168,639 -14,388	-8%	-$98.9K	﹤0.01%	1836
2024 Q1	$1.93M	Buy	+183,027	New	+$2.1M	﹤0.01%	1380

Other funds holding MGX

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace's MGX Position: Q1 2026 in Review

Marshall Wace reduced its Metagenomi Therapeutics (MGX) stake by 65% in Q1 2026, selling an estimated $80.2K and leaving 27,521 shares worth $36.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3005.

Marshall Wace first reported a position in MGX in Q1 2024 and has held it in 8 quarters since. The position peaked at $1.93M in Q1 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

Marshall Wace held 27,521 shares of Metagenomi Therapeutics worth $36.9K as of Q1 2026.
Marshall Wace sold 51,615 Metagenomi Therapeutics shares in Q1 2026, an estimated $80.2K.
Metagenomi Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #3005 holding.
Marshall Wace first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 8 quarters since.
Marshall Wace's Metagenomi Therapeutics position peaked at $1.93M in Q1 2024.
48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.